251 related articles for article (PubMed ID: 22372201)
1. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia.
McGregor S; McNeer J; Gurbuxani S
Semin Diagn Pathol; 2012 Feb; 29(1):2-11. PubMed ID: 22372201
[TBL] [Abstract][Full Text] [Related]
2. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
3. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic, cytogenetic and clinical features of 113 acute lymphoblastic leukaemia patients in China.
Tong H; Zhang J; Lu C; Liu Z; Zheng Y
Ann Acad Med Singap; 2010 Jan; 39(1):49-53. PubMed ID: 20126815
[TBL] [Abstract][Full Text] [Related]
6. Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
Wenzinger C; Williams E; Gru AA
Curr Hematol Malig Rep; 2018 Aug; 13(4):275-288. PubMed ID: 29951888
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
8. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
[TBL] [Abstract][Full Text] [Related]
10. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
11. Immunological Subtypes of Acute Lymphoblastic Leukemia- Beyond Morphology: Experience from Kidwai State Cancer Institute, Bengaluru, India.
Rajkumar NN; Vijay RH
J Assoc Physicians India; 2017 Jul; 65(7):14-17. PubMed ID: 28792162
[TBL] [Abstract][Full Text] [Related]
12. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
Schrappe M; Valsecchi MG; Bartram CR; Schrauder A; Panzer-Grümayer R; Möricke A; Parasole R; Zimmermann M; Dworzak M; Buldini B; Reiter A; Basso G; Klingebiel T; Messina C; Ratei R; Cazzaniga G; Koehler R; Locatelli F; Schäfer BW; Aricò M; Welte K; van Dongen JJ; Gadner H; Biondi A; Conter V
Blood; 2011 Aug; 118(8):2077-84. PubMed ID: 21719599
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers in ALL: Clinical implications.
Kimura S; Mullighan CG
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101193. PubMed ID: 33038982
[TBL] [Abstract][Full Text] [Related]
14. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
15. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Receptor Rearrangements Determined Using Fragment Analysis in Patients With T-Acute Lymphoblastic Leukemia.
Kim H; Kim IS; Chang CL; Kong SY; Lim YT; Kong SG; Cho EH; Lee EY; Shin HJ; Park HJ; Eom HS; Lee H
Ann Lab Med; 2019 Mar; 39(2):125-132. PubMed ID: 30430774
[TBL] [Abstract][Full Text] [Related]
18. International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
Duffield AS; Mullighan CG; Borowitz MJ
Virchows Arch; 2023 Jan; 482(1):11-26. PubMed ID: 36422706
[TBL] [Abstract][Full Text] [Related]
19. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
20. New genetic abnormalities and treatment response in acute lymphoblastic leukemia.
Meijerink JP; den Boer ML; Pieters R
Semin Hematol; 2009 Jan; 46(1):16-23. PubMed ID: 19100364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]